Drug licenses: A new model for pharmaceutical pricing

Health Affairs

Volumn 27, Issue 1, 2008, Pages 122-129

  Goldman, Dana P ^a   Jena, Anupam B ^b   Philipson, Tomas ^c   Sun, Eric ^b  

^a RAND CORPORATION   (United States)

^b Bing Center

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

DRUG COST; DRUG INDUSTRY; DRUG USE; ECONOMICS; FEE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; LEGAL ASPECT; LICENSING; PATIENT COMPLIANCE; PRESCRIPTION; PROFIT; REVIEW; STATISTICAL MODEL; UNITED STATES;

DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, PHARMACEUTICAL SERVICES; LICENSURE; MODELS, ECONOMIC; PRESCRIPTION FEES; UNITED STATES;

EID: 38849088105     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.27.1.122     Document Type: Review

References (21)

1. Organization for Economic Cooperation and Development, OECD Health Data 2005: A Comparative Analysis of Thirty Countries (Paris: OECD, 2005).
2. C.W. Tseng et al., "Cost-Lowering Strategies Used by Medicare Beneficiaries Who Exceed Drug Benefit Caps and Have a Gap in Drug Coverage," Journal of the American Medical Association 292, no. 8 (2004): 952-960.
3. Harris Interactive, "Prescription Drug Compliance a Significant Challenge for Many Patients, According to New National Survey," 29 March 2005, http://www.harrisinteractive.com/news/allnewsbydate.asp?NewsID=904 (accessed 16 September 2007).
4. See, for example, D.P. Goldman et al., "Pharmacy Benefits and the Use of Drugs by the Chronically Ill," Journal of the American Medical Association 291, no. 19 (2004): 2344-2350;
5. G.F. Joyce et al., "Employer Drug Benefit Plans and Spending on Prescription Drugs," Journal of the American Medical Association 288, no. 14 (2002): 1733-1739;
6. R.E. Johnson et al., "The Impact of Increasing Patient Prescription Drug Cost Sharing on Therapeutic Classes of Drugs Received and on the Health Status of Elderly HMO Members," Health Services Research 32, no. 1 (1997): 103-122;
7. and T.S. Rector et al., "Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications," Medical Care 41, no. 3 (2003): 398-406.
8. A. Dor and W. Encinosa, "Does Cost Sharing Affect Compliance? The Case of Prescription Drugs," NBER Working Paper no. 10738 (Cambridge, Mass.: National Bureau of Economic Research, 2005);
9. N. Lurie et al., "Termination of Medi-Cal Benefits: A Follow-Up Study One Year Later," New England Journal of Medicine 314,no. 19 (1986): 1266-1268;
10. D.P. Goldman, G.F. Joyce, and P. Karaca-Mandic, "Varying Pharmacy Benefits with Clinical Status: The Case of Cholesterol-Lowering Therapy," American Journal of Managed Care 12, no. 1 (2006): 21-28;
11. and R. Tamblyn et al., "Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons," Journal of the American Medical Association 285, no. 4 (2001): 421-429.
12. M. Angell, The Truth about the Drug Companies: How They Deceive Us and What to Do about It (New York: Random House, 2004).
13. P.M. Danzon, Y.R. Wang, and L. Wang, "The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-five Major Markets in the 1990s," Health Economics 14, no. 3 (2005): 269-292;
14. P.M. Danzon and J.D. Ketcham, "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand," NBER Working Paper no. 10007 (Cambridge, Mass.: NBER, October 2003);
15. and D. Acemoglu and J. Linn, "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Quarterly Journal of Economics 119, no. 3 (2004): 1049-1090.
16. A. Garber, C. Jones, and P. Romer, "Insurance and Incentives for Medical Innovation," Forum for Health Economics and Policy 9, no. 2 (2006): 1-27;
17. and T. Philipson, S. Mechoulan, and A.B. Jena, "IP and External Consumption Effects: Generalizations from Health Care Markets," NBER Working Paper no. 11930 (Cambridge, Mass.: NBER, January 2006).
18. Goldman et al., "Varying Pharmacy Benefits."
19. J.S. Schultz et al., "Determinants of Compliance with Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population," American Journal of Managed Care 11, no. 5 (2005): 306-312.
20. L. Wei et al., "Adherence to Statin Treatment and Readmission of Patients after Myocardial Infarction: A Six Year Follow Up Study," Heart 88, no. 3 (2002): 229-233.
21. A.M. Fendrick et al., "A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost," American Journal of Managed Care 7, no. 9 (2001): 861-867.